Pioglitazone, a PPAR-γ Activator, Attenuates the Severity of Cerulein-Induced Acute Pancreatitis by Modulating Early Growth Response-1 Transcription Factor

Hongyu Wan,Yaozong Yuan,Jiansheng Liu,Guohong Chen
DOI: https://doi.org/10.1016/j.trsl.2012.02.003
IF: 10.171
2012-01-01
Translational Research
Abstract:The purpose of this study was to test the hypothesis that activation of endogenous peroxisome proliferator-activated receptor (PPAR gamma) inhibits induction of early growth response factor-1 (Egr-1), which is rapidly induced in the pancreas following cerulein intraperitoneal injection. Acute pancreatitis was induced in mice by hourly intraperitoneal injection of cerulein. Pioglitazone was administered prophylactically and pancreatic inflammation was assessed. AR42J cells were stimulated with caerulein 10(-8)M co-incubated in presence of different concentration of pioglitazone. The expression of PPAR gamma, Egr-1, and the target genes of Egr-1 were studied by real-time reverse transcriptase polymerase chain reaction (PCR), Western blot, and immunohistochemistry. In vitro, a PPAR-gamma activator (pioglitazone) strikingly diminished Egr-1 mRNA and protein expression corresponding to Egr-1. In vivo, treatment with pioglitazone prior to the intraperitoneal injection of cerulein induction of Egr-1 and its target genes such as, monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1). The inhibitory effect of pioglitazone on Egr-1 expression induced by cerulein was almost fully restored by GW9662. Activation of PPAR-gamma suppressed the activation of Egr-1 and its inflammatory gene targets and provided potent protection against pancreas injury. These data suggest a new mechanism in which PPAR-gamma activation may decrease tissue inflammation in response to a cerulein insult. (Translational Research 2012;160:153-161)
What problem does this paper attempt to address?